Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | WNT1 | P04628 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24605640 | 1.00 | ABL1 (0.48) | ABL1GSK3BWNT1DYRK1ALYN | |
| SCHEMBL29776453 | 0.91 | ABL1 (0.50) | ABL1GSK3BLYNSRCBTK | |
| SCHEMBL24605593 | 0.91 | ABL1 (0.50) | ABL1GSK3BLYNSRCBTK | |
| SCHEMBL29776236 | 0.88 | ABL1 (0.53) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL27196862 | 0.88 | ABL1 (0.53) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL27197027 | 0.81 | ABL1 (0.44) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL27196991 | 0.81 | ABL1 (0.44) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL27196994 | 0.81 | ABL1 (0.44) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL29776447 | 0.80 | ABL1 (0.60) | ABL1GSK3BWNT1DYRK1A | |
| SCHEMBL24605633 | 0.80 | ABL1 (0.60) | ABL1GSK3BWNT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | claimed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | ABL1 1664/4885GSK3B 106/4885WNT1 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.